ArticleFrontiers in oncology2026
Levels of chronic systemic inflammation markers in patients with multi-stages of esophageal and gastric lesions.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic systemic inflammation (CSI) is linked to esophageal and gastric cancer (EC and GC) risk. However, few studies have explored the potential role of CSI markers in the development of EC/GC, from normal mucosa, benign lesion to carcinomatous degeneration. Methods: This case-control study was based on a population-based EC&GC screening program in a high-incidence area of China. For esophageal lesions, 633 participants from groups with normal mucosa (E-con, N = 202), benign lesion (E-BL, N = 229), and precancerous lesion/cancer (E-case, N = 202, matched with E-con) were included. For gastric lesions, 156 pairs of samples from four groups with normal/superficial gastritis (G-con), atrophic gastritis (AG), intestinal metaplasia (IM), and precancerous lesion/cancer (G-case) were matched. Multivariable logistic regression was used to explore the association between CSI markers and esophageal/gastric lesions. Results: Among 13 CSI indicators, E-case group showed a slightly lower mean platelet volume (MPV) level than E-con or E-BL group. In logistic regression models, MPV was negatively associated with E-case risk compared to E-con (OR = 0.65, 95%CI: 0.46-0.92) or (E-con+E-BL) group (OR = 0.81, 95%CI: 0.68-0.97). The levels of 13 CSI markers were similar across four gastric lesion groups. However, lower MPV was associated with an increased risk of AG (OR = 0.70, 95%CI: 0.50-0.97), IM (OR = 0.62, 95%CI: 0.45-0.86), G-case (OR = 0.56, 95%CI: 0.37-0.86), and all three lesion (AG+IM+G-case, OR = 0.69, 95%CI: 0.52-0.93) compared to G-con group. Conclusion: MPV was negatively associated with the risk of esophageal precancerous lesion/cancer, and also likely associated with an decreased risk of AG and more severe lesions in Correa's cascade of pathological process of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.